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In	recent	years,	one	of	the	main	focuses	in	investi-
gation	of	B-cell	chronic	lymphocytic	leukemia	(B-CLL)	
pathogenesis	consists	in	the	study	of	antigenic	influ-
ence	as	possible	 initial	stimulus	 for	development	of	
malignant	 lymphoid	clone	 [1].	Now	B-CLL	 is	 con-
sidered	as	disease	of	 immunologically	 competent	
B-lymphocytes	that	undergo	antigen	selection	[2,	3].	
Investigation	of	 variable	 (V),	diversity	 (D),	and	 joint	
(J)	 immunoglobulin	 (IG)	heavy	 (H)	chain	genes	are	
used	 to	construct	of	B-cell	antigen	 receptor	 (BCR)	
revealed	nonstochastic	distribution	that	was	differed	
from	expected	random	assortment	and	from	normal	
peripheral	blood	B-lymphocytes.	Besides	this,	more	
than	20%	of	B-CLL	patients	from	different	geographic	
regions	have	very	similar	BCR	structures	with	high	
degree	of	homology	in	third	complementarity	deter-
mining	regions	(CDR3)	of	both	heavy	and	light	(L)	im-
munoglobulin	chains	[4].	As	the	probability	of	specific	
IGHV/IGHD/IGHJ	rearrangement	together	with	IGLV/
IGLJ	rearrangement	is	1	in	1.32	million,	the	antigenic	
influence	on	CLL	cell	clone	seems	important.	
Now	48	B-CLL	subsets	with	stereotyped	HCDR3	
are	described	[4].	The	most	frequently	homologous	
HCDR3	are	 found	among	cases	with	 IGHV1-69	and	
IGHV3-21	 gene	 usage.	CLL	 cases	with	 IGHV3-21	
gene	usage	now	are	considered	as	distinct	entity	with	
restricted	 immunoglobulin	gene	 features	and	poor	
prognosis	[5].	Overrepresentation	of	IGHV3-21	gene	
was	first	revealed	in	Scandinavian	cohort	of	CLL	pa-
tients	(11.7%),	and	the	most	of	presented	IGHV3-21	
cases	had	HCDR3	conservative	amino	acid	sequence	
consisted	of	a	Ala-Arg-Asp-Ala-Asn-Gly-Met-Asp-Val	
(ARDANGMDV)	motif	(CLL	subset	#2)	[6,	7].	It	is	well	
known	that	the	absence	of	somatic	hypermutations	in	
the	 IGHV	genes	is	negative	prognostic	factor	in	CLL	
[8,	9],	but	mutated	 IGHV3-21	 cases	 (most	of	 them	
with	ARDANGMDV	motif)	had	worse	overall	survival,	
which	was	significantly	different	 from	the	 remaining	
mutated	CLL	 cases	 and	 similar	 to	 the	 unmutated	
group	 [7].	These	data	were	confirmed	 in	studies	of	
British	and	Belgian	CLL	patients	[10,	11].	P.	Ghia	et	al.	
[5]	have	shown	that	worse	prognosis	was	typical	first	
of	all	for	homogeneous	HCDR3	subset	(homHCDR3)	
while	 IGHV3-21	 cases	with	heterogeneous	HCDR3	
(heteroHCDR3)	had	variable	clinical	course.	They	also	
reported	 that	 IGHV3-21	gene	widely	 represented	 in	
Northern	Europe	was	found	only	in	2.9%	CLL	patients	
from	the	Mediterranean	area	(France,	Greece,	 Italy,	
Spain).	The	comprehensive	study	of	1076	CLL	cases	
from	Northern,	Central	and	Southern	Italy	confirmed	
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relatively	low	frequency	of	IGHV3-21	gene	usage	in	this	
region	(3.4%)	and	worse	prognosis	for	homogeneous	
HCDR3	subset,	but	also	revealed	nonrandom	distribu-
tion	of	homHCDR3	and	heteroHCDR3	subsets:	the	first	
was	found	almost	exclusively	in	Northern	Italy	(16	of	
18	cases)	and	the	last	(19	cases)	was	uniformly	dis-
tributed	throughout	Italy	[12].	The	assumption	about	
different	antigenic	 influence	 in	certain	geographic	
regions	was	proposed.
The	aim	of	this	work	was	to	study	the	frequency	of	
IGHV3-21	gene	usage	and	its	clinical	significance	in	
Ukrainian	CLL	cohort.
MATERIALS AND METHODS
A	total	of	189	CLL	patients	from	different	regions	
of	Ukraine,	mainly	from	its	Central	part,	were	studied	
for	 IGHV	gene	usage	and	mutation	status	(Table	1).	
The	diagnosis	of	CLL	was	based	on	clinical	history,	
lymphocyte	morphology,	and	immunophenotypic	cri-
teria.	Stage	of	disease	was	established	according	to	
classifications	of	Rai	[13],	Binet	[14]	and	International	
Workshop	on	Chronic	Lymphocytic	Leukemia	[15].
Table 1. Observed CLL patients, region of Ukraine, number of patients
Western Ukraine Central Ukraine Southern Ukraine Eastern Ukraine
L’viv 4 Kiyv 59 Odessa 2 Dnepropetrovsk 9
Luzk 2 Poltava 67 Nikolaev 1 Donesk 9
Rivne 2 Sumy 4 Crimea 3 Lugansk 5
Ternopyl 1 Cherkassy 8 Charkiv 1
Chmelnizkiy 2
Zhitomir 6
Chernovzy 1
Vinniza 3
Total cases 21 Total 138 Total 6 Total 24
IGHV3-21 
gene positive 
cases 
0 9 0 2
Total	RNA	was	extracted	 from peripheral	blood	
and/or	bone	marrow	cells	 using	guanidine	 isotio-
cyanate-phenol-chlorophorm	extraction	according	
to	Chomczynski	[16].	1–5	μg	of	the	total	cellular	RNA	
was	reverse	transcribed	to	cDNA	using	MuLV	reverse	
transcriptase	enzyme	 (Applied	Biosystem,	Branch-
burg,	New	Jersey,	USA)	and	random	hexamers	as	pri-
mers.	cDNA	was	amplified	in	a	single	multiplexed	PCR	
reaction	consisting	of	six	IGHV	framework	1	primers	
combined	with	 IGHJ	consensus	primer	as	designed	
by	the	BIOMED-2	consortium	[17].	All	reactions	were	
carried	out	in	final	volume	of	50	μl	with	10	pmol	of	each	
primer,	200	nM	dNTPs,	1	U	AmpliTaq	Gold	and	10	x	
PCR	buffer	II	(Applied	Biosystems,	Branchburg,	New	
Jersey,	USA).	The	cycling	conditions	were	as	follows:	
preactivation	at	94	°C	for	7	min;	35	cycles	of	94	°C	for	
45	s,	60	°C	for	45	s	and	72	°C	for	45	s;	a	final	cycle	of	
10	min	at	72	°C.
PCR	products	were	analyzed	on	a	1.5%	agarose	gel	
and	visualized	with	ethidium	bromide	staining.	Products	
were	spin	column	purified	using	PCR	purification	kit	
(Promega,	Madison,	WI)	and	sequenced	directly	using	
forward	and	reverse	primers	in	an	automated	DNA	se-
quencer	ABI-310	(Applied	Biosystem,	Foster	City,	CA)	
using	BigDye	Terminator	Cycle	Sequencing	Reaction	
Kit	(Perkin	Elmer,	Foster	City,	CA).	The	closest	germ-
line	 IGHV	gene	 for	each	B-CLL	 IGHV	sequence	was	
assigned	using	current	databases	IMGT	(International	
Immunogenetics	Database)	[18],	IgBlast	(National	Cen-
ter	for	Biotechnology	Information,	Bethesda,	MD),	and	
JoinSolver	[19].	IGHV	gene	sequences	deviating	more	
than	2%	from	the	corresponding	germline	gene	were	
defined	as	mutated.	For	IGHD	gene	determination,	a	
requirement	of	a	minimum	of	7	matching	nucleotides	
was	used.	The	 length	of	 the	HCDR3	was	calculated	
followed	established	IMGT	criteria.
In	some	cases	with	homologous	IGHV	sequences	
we	amplified	 immunoglobulin	 variable	 light	 kappa	
or	 lambda	chains	 (IGKV	and	 IGLV)	according	 to	 the	
BIOMED-2	protocol	[17].
Statistics	was	performed	using	 the	SPSS	13.0	
software	package	(SPSS,	Chicago,	IL).
RESULTS
IGHV gene usage and mutation status. Produc-
tive	IGHV-D-J	rearrangements	were	sequenced	in	all	
189	CLL	patients.	Using	the	98%	cut	off	for	homology	
to	germ	line,	55	(29.1%)	cases	were	classified	as	mu-
tated	with	a	mean	mutation	frequency	of	7.3%	(range,	
3.6–11.6%).	 The	 remaining	 134	 rearrangements	
(70.9%)	showed	<2%	mutations	and	were	classified	
as	unmutated.	
The	top	10	most	used	IGHV	genes	in	this	CLL	co-
hort	were	IGHV1-69	(41	cases;	21.7%),	IGHV4-34	(14;	
7.4%),	IGHV3-21	and	IGHV3-33	(each	11	cases;	5.8%),	
IGHV1-02	(10;	5.3%),	IGHV3-07	(9;	4.8%),	IGHV3-48	
and	 IGHV3-09	 (each	8	 cases;	 4.2%),	 followed	by	
IGHV3-11,	 IGHV4-59,	and	 IGHV3-30	 (each	7	cases,	
3.7%).	There	were	prevalence	of	unmutated	cases	
and	increased	frequency	of	IGHV1-69	and	IGHV3-09	
gene	positive	cases	in	our	cohort	in	comparison	with	
previously	published	data	[20–22].	The	frequency	of	
IGHV3-21	gene	usage	 (5.8%)	was	 intermediate	be-
tween	Scandinavian	(11.7%)	and	Mediterranean	CLL	
(2.9%)	cohorts.	There	were	no	differences	in	frequen-
cy	of	IGHV3-21	gene	usage	in	patients	from	different	
regions	of	Ukraine	probably	because	of	the	prevalence	
of	observed	patients	from	the	Central	part.
Six	 (54.5%)	 IGHV3-21	 positive	cases	were	mu-
tated	with	a	mean	mutation	frequency	of	4.3%	(range,	
2.7–6.8%),	and	4	cases	had	low	level	of	IGHV	muta-
tions	(between	2	and	4%)	that	is	typical	for	mutated	
IGHV3-21	gene	used	cases	[10].	IGHV3-21	gene	was	
on	 the	 third	 position	within	 the	mutated	 subset	
(10.9%),	where	IGHV4-34	followed	by	IGHV3-07	were	
the	most	represented	IGHV	genes.	In	the	unmutated	
subset	IGHV3-21	gene	(5	cases)	shared	5-9	positions	
with	IGHV3-09,	IGHV3-30,	IGHV3-48,	and	IGHV4-59	
genes	by	the	frequency	of	usage	(Table	2).	
Table 2. IGHV gene usage in all mutated and unmutated cases
Rank Mutated IGHV gene % (n cases)
Unmutated 
IGHV gene % (n cases)
1 IGHV4-34 20 (11) IGHV1-69 29.9 (40)
2 IGHV3-07 14.5 (8) IGHV1-02 6.7 (9)
3 IGHV3-21 10.9 (6) IGHV3-33 6.7 (9)
4 IGHV3-09 5.5 (3) IGHV3-11 4.8 (6)
5 IGHV3-23 5.5 (3) IGHV3-09 3.7 (5)
6 IGHV3-48 5.5 (3) IGHV3-21 3.7 (5)
7 IGHV3-53 5.5 (3) IGHV3-30 3.7 (5)
8 IGHV3-15 3.6 (2) IGHV3-48 3.7 (5)
9 IGHV4-59 3.6 (2) IGHV4-59 3.7 (5)
10 IGHV3-30 3.6 (2) IGHV4-39 3.0 (4)
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Only	two	(18.2%)	IGHV3-21	cases	(both	mutated)	
in	our	CLL	group	belonged	to	subset	#2	with	homo-
geneous	HCDR3	 (EF407845	and	EF407838).	Their	
HCDR3	sequences	were	 identical,	and	 their	LCDR3	
differed	only	by	one	amino	acid,	to	the	sequences	pub-
lished	early	(Table	3).	Nine	IGHV3-21	cases	belonged	
to	the	so-called	heterogeneous	HCDR3	subset	with	
unrelated	HCDR3	rearrangements,	but	we	found	that	
3	of	them	(EF091900,	EF091902,	and	EF407842)	had	
showed	homology	with	heteroHCDR3	IGHV3-21	cases	
from	another	CLL	cohorts.	Besides	 this,	HCDR3s	
of	 two	another	our	heterogeneous	 IGHV3-21	 cases	
(EF091901	and	EF407825)	had	some	similarity	with	
HCDR3s	 of	 previously	 described	 IGHV3-09	 and	
IGHV1-69	cases	respectively	(see	Table	3).	All	of	these	
cases	were	unmutated,	so	all	5	unmutated	IGHV3-21	
cases	in	our	group	had	similarity	of	their	HCDR3	with	
another	sequences.
Clinical data. IGHV3-21	 gene	expression	was	
found	 in	 8	men	and	3	women	with	 the	mean	age	
57.7	years	at	the	diagnosis	(range,	41–73	years).	The	
mean	age	and	male/female	distribution	did	not	differ	
from	CLL	patients	with	the	other	than	IGHV3-21	gene	
usage	(136	men,	42	women,	mean	age,	56.9	years).
CD38	 expression	was	 studied	 in	 155	 patients	
using	by	two-color	fluorescence-activated	cell	sort-
ing	 (FACS)	analysis.	High	 level	of	CD38	expression	
(>	30%)	was	found	in	6	of	10	(60%)	IGHV3-21	positive	
patients	and	in	47	of	145	(32.4%)	the	other	CLL	patients	
(p	=	0.07),	and	the	mean	of	CLL	cells	expressing	CD38	
was	higher	in	IGHV3-21	subgroup	(40.2%	vs	22.2%,	
p	=	0.03).	It	is	interesting	that	level	of	CD38	expression	
did	not	differ	between	mutated	and	unmutated	cases	
in	the	whole	group	of	CLL	patients	(18.8%	vs	25.1%;	
p	=	0.19),	but	when	IGHV3-21	positive	cases	had	been	
excluded,	these	differences	obtained	statistical	signifi-
cance	(15.2%	vs	24.6%;	p	=	0.02).	At	the	same	time	
within	IGHV3-21	subgroup	number	of	CD38	expressing	
CLL	cells	was	similar	in	mutated	and	unmutated	cases	
(43.7%	vs	36.6%, p	=	0.73).
Despite	of	low	numbers	of	IGHV3-21	cases	in	our	
CLL	group	we	found	clear	differences	between	mu-
tated	and	unmutated	cases	regarding	of	 treatment-
free	survival	(TFS,	median	48	months	and	7	months,	
correspondingly,	p	=	0.04),	progression-free	survival	
(PFS,	median	108	months	and	22	months,	p	=	0.006),	
and	overall	 survival	 (OS,	median	did	not	 reach	and	
43	months	correspondingly,	p	=	0.02).	
There	were	no	statistically	significant	differences	
between	mutated	IGHV3-21	cases	and	mutated	cases	
that	expressed	the	others	IGHV	genes	in	OS,	TFS,	and	
PFS	(Table	4).	But	unmutated	 IGHV3-21	expressing	
cases	in	comparison	with	the	other	unmutated	cases	
were	characterized	worse	OS	(median	43	months	and	
90	months,	p	=	0.0008),	and	PFS	(median	22	months	
and	48	months,	p	=	0.06),	while	median	TFS	curves	
were	similar	(7	months	and	9	months,	p >	0.05).	When	
IGHV3-21	cases	were	analyzed	as	a	whole	group,	the	
differences	in	OS,	PFS,	and	TFS	were	insignificant	in	
comparison	with	the	remaining	unmutated	and	the	re-
maining	mutated	CLL	cases	as	well	as	both	of	them.
Table 4. Survival parameters of observed CLL patients
Patients
Median survival curves, 
months
TFS PFS OS
All CLL patients, n = 189 12 52 106
Only IGHV3-21 cases, n = 11 34 72 107
CLL patients excluding IGHV3-21 cases, n = 178 12 50 101
Mutated cases
All mutated cases, n = 55 24 77 Did not reach
Mutated IGHV3-21 cases, n = 6 48 108 Did not reach
Mutated cases excluding IGHV3-21, n = 49 15 77 Did not reach
Unmutated cases
All inmutated cases, n = 134 9 43 90
Unmutated IGHV3-21 cases, n = 5 7 22 43
Unmutated cases excluding IGHV3-21, n = 129 11 48 90
Remarkable	feature	of	 IGHV3-21	expressing	CLL	
patients	was	high	incidence	of	solid	tumors.	They	have	
developed	in	4	patients:	prostate	cancer	(180	months	
before	CLL	diagnosis;	unmutated,	heteroHCDR3	sub-
set),	colon	cancer	(simultaneously	with	CLL	diagnosis,	
mutated,	 heteroHCDR3	 subset),	 stomach	 cancer	
(84	months	after	CLL	diagnosis,	mutated,	hetero-
HCDR3	subset),	and	prostate	cancer	 (228	months	
after	CLL	diagnosis,	mutated,	homoHCDR3	subset).	
Among	178	CLL	patients	expressing	 the	other	 IGHV	
genes,	secondary	solid	tumors	were	diagnosed	only	
in	10	cases	 (5.6%,	p	=	0.0002)	—	one	case	 (2.0%)	
within	mutated	subgroup	and	9	cases	(7.0%)	within	
unmutated	subgroup.	The	frequency	of	solid	tumor’s	
development	within	 IGHV3-21	 used	mutated	cases	
was	 too	much	higher	 than	among	mutated	cases	
expressed	 the	others	 IGHV	genes	 (50%	vs	2%;	p	<	
0.001).	For	unmutated	cases	this	difference	was	in-
significant	regardless	to	 IGHV3-21	gene	usage.	The	
frequency	of	Richter	 transformation	did	not	differ	
Table 3. IGHV3-21 CLL cases with homologous IGHV sequences, (-) indicate homology
N Case HCDR3 aa sequences; HCDR3 aa identity between presented paired sequences# IGKV/IGLV gene and K/LCDR3 sequence
1 EF407845* …AR DMNAMDV IGLV3-21; QVWDSSSDHPWV
ITA-1 [4] …AR -------HCDR3 homology 100% IGLV3-21; QVWDSGSDHPWV
2 EF407838* …AR DANGMDV IGLV3-21; QVWDSSSDHPWV
P1531 [4] …AR -------HCDR3 homology 100% IGLV3-21; QVWDSGSDHPWV
3 EF091900* …AR DRGVSSSWYLSYYYYMDV 
Case28 [7] …AR V--------A-------- HCDR3 homology 90%
4 EF091902*  …AR NRYTEYCSSTSCHPSYYYYYGMDV
Gre6 [5] …AR D-LLG-------WD ---------HCDR3 homology 73.1%  
5 EF407842* …AR DSDYDFWSGSWGYYGMDV  IGKV2-30; MQGTHWPPT
DQ987781* …AR –G-------Q-------- HCDR3 homology 90%
6 EF091901* [23] …AR DGLYDFWSGYGN
…AR   H-------P-LSPFDY
7 EF407825* …AR DGGSLYYDILTGYYSLEYYYGMDV IGKV1-9; RQLNSYPLFT
FRA-132 [4] …AR E-- -R------- -EY-------
*GenBank database accession numbers.
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significantly	between	IGHV3-21	gene	used	cases	(one	
case,	9.1%)	and	the	other	IGHV	gene	used	subgroup	
(10	cases,	5.6%)	as	well	as	frequency	of	autoimmune	
disorders	(9.1%	vs	7.9%,	p	>	0.05).	
Special	attention	was	devoted	to	cases	with	short	
homogenous	HCDR3	sequence.	Both	of	 them	were	
diagnosed	in	A(I)	stage,	did	not	need	treatment	over	
a	 long	period	of	 time	(96	months	and	183	months),	
and	had	 long	PFS	 (120	months	and	233	months).	
However,	in	one	patient	disease	was	complicated	by	
development	of	prostate	cancer,	and	second	patient	
underwent	Richter	transformation.	
DISCUSSION
In	our	 study	 IGHV3-21	 gene	was	 found	 in	11	of	
189	productive	IGHV-D-J	rearrangements	(5.8%).	So,	
as	was	mentioned	above,	the	frequency	of	IGHV3-21	
gene	usage	in	Ukrainian	CLL	group	was	intermediate	
between	Scandinavian	[6,	7]	and	Mediterranean	co-
horts	[5]	of	patients	that	might	have	supposed	in	view	
of	geographical	position	of	Ukraine.	But	 in	contrast	
to	others	authors	 the	most	of	our	cases	belonged	
to	so-called	heteroHCDR3	subset	(9	of	11)	and	only	
two	 had	 short	 ARDANGMDV	motif.	 For	 example,	
21	of	31	 IGHV3-21	Scandinavian	cases	belonged	 to	
the	homoHCDR3	subset	 [7]	and	 the	 ratio	of	homo/
hetero	HCDR3	subsets	was	approximately	equal	 in	
Mediterranean	study	(7/9)	[5]	and	Italian	multicenter	
study	(18/19)	[12].	Besides	this,	our	two	patients	with	
IGHV3-21	 and	 IGLV3-21	 genes	usage	 from	homo-
HCDR3	subset	had	had	 indolent	disease	 for	a	 long	
time,	while	the	poor	prognosis	of	IGHV3-21	expressing	
cases	is	related	namely	with	homoHCDR3	subset.	The	
differences	in	the	frequency	of	individual	IGHV	gene	
usage	in	different	CLL	cohort	in	many	respects	may	be	
related	with	basic	characteristics	of	observed	patients.	
Mainly	hospital	patients	with	severe	course	of	disease	
and	mostly	unmutated	IGHV	gene	usage	represented	
our	cohort.	So,	in	our	group	it	would	rather	expect	de-
creasing	frequency	of	some	IGHV	genes	(for	example,	
IGHV3-07)	associated	with	favorable	prognosis	than	
IGHV3-21	positive	cases	with	assumed	bad	prognosis.	
Therefore	we	supposed	that	the	frequency	of	IGHV3-21	
cases	with	homologous	HCDR3	was	really	low	in	the	
group	of	CLL	patients	 from	Central	part	of	Ukraine	
and	the	influence	of	hypothetic	antigen	specific	to	the	
common	HCDR3	and	LCDR3	was	not	such	significant	
as	 in	Northern	European	countries.	Low	 frequency	
of	homoHCDR3	subset	within	 IGHV3-21	expressing	
cases	was	also	revealed	in	Southern	and	Central	Italy,	
and	Greek	(one	of	7	cases)	[5].
Concerning	 to	 IGHV3-21	 expressing	cases	with	
heterogeneous	HCDR3	P.	Ghia	et	al.	[5]	supposed	that	
this	subset	might	reflect	normal	repertoire	of	human	
peripheral	blood	B-lymphocytes.	We	observed	9	cases	
belonged	 to	heteroHCDR3	subset,	4	of	 them	were	
mutated,	and	5	were	unmutated.	 It	was	 interesting	
that	for	all	5	unmutated	heteroHCDR3	cases	we	found	
some	similar	HCDR3	sequences	published	earlier.	So,	
it	is	possible,	that	expression	of	IGHV3-21	gene	with	
heterogeneous	HCDR3	 is	non-stochastic	and	also	
reflects	possible	antigenic	stimulation.	
We	did	not	reveal	statistically	significant	differences	
in	OS,	PFS,	and	TFS	for	 IGHV3-21	positive	cases	 in	
comparison	with	CLL	 cases	 expressing	 the	other	
IGHV	genes.	These	survival	parameters	of	mutated	
IGHV3-21	 gene	used	cases	were	comparable	with	
mutated	cases	that	expressed	the	others	IGHV	genes.	
But	 remarkable	 feature	of	mutated	 IGHV3-21	cases	
was	high	frequency	of	solid	tumors	developed	before	
or	after	CLL	diagnosis.	Their	presence	significantly	
complicated	life	quality	of	CLL	patients,	required	ope-
rative	treatment	in	all	cases,	and	was	direct	cause	of	
death	of	one	patient.	Thus,	in	small	group	of	6	patients	
with	mutated	IGHV3-21	gene	expression	3	patients	had	
solid	tumors	and	one	underwent	Richter	transforma-
tion.	Unmutated	IGHV3-21	gene	expressed	cases	had	
worse	OS	and	PFS	in	comparison	with	unmutated	CLL	
cases	that	expressed	the	others	genes.	These	data	are	
in	agreeing	with	the	opinion	about	negative	prognostic	
significance	of	IGHV3-21	gene	expression	regardless	
its	mutation	status.
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ЭКСПРЕССИЯ ГЕНА IGHV3-21 У БОЛЬНЫХ ХРОНИЧЕСКИМ 
ЛИМФОЛЕЙКОЗОМ В УКРАИНЕ
Цель: оценить частоту использования гена IGHV3-21 и его клиническое значение для больных B-клеточны�� х�онически��  
ли��фолейкозо�� (ХЛЛ) в Ук�аине. Больные и методы исследования: �епе�туа� генов ва�иабельных участков тяжелых цепей 
и����уноглобулинов (IGHV) изучали у 189 больных с ХЛЛ с по��ощью поли��е�азной цепной �еакции на базе об�атной т�анск�ипции 
и п�я��ого сиквенса а��плифици�ованных п�одуктов. Результаты: эксп�ессия гена IGHV3-21 выявлена у 11 пациентов (5,8%), 
что зани��ает п�о��ежуточное положение ��ежду Скандинавской (11,7%) и С�едизе��но��о�ской (2,9%) кого�та��и. Большинство 
случаев (9 из 11) относились к подг�уппе с гете�огенны�� т�етьи�� ко��пле��ента�ны�� �егионо�� (heteroHCDR3 подг�уппа) и только    
2 случая — к подг�уппе с ко�отки�� классически�� ARDANGMDV ��отиво�� (homHCDR3-подг�уппа). �есть    IGHV3-21-пози-
тивных случаев были ��ути�ованны��и и 5 — не��ути�ованны��и. Все не��ути�ованные случаи (все из heteroHCDR3-подг�уппы) 
и��ели сходство HCDR3 с �анее описанны��и последовательностя��и. �азличия в общей выживае��ости (OS), длительности           
пе�иода до п�ог�ессии заболевания (PFS) и начала лечения (TFS) для      IGHV3-21-позитивных больных были статистически 
незначи��ы по с�авнению с пациента��и с ХЛЛ с эксп�ессией д�угих IGHV-генов. Указанные па�а��ет�ы также с�авнивали 
��ежду больны��и ХЛЛ с эксп�ессией ��ути�ованных IGHV3-21- и д�угих IGHV-генов. Отличительной че�той пациентов с 
эксп�ессией IGHV3-гена была высокая вст�ечае��ость солидных опухолей. Они �азвились в 4 IGHV3-21-позитивных случаях 
(36,4%) и в 10 случаях с эксп�ессией д�угих IGHV-генов (5,6%, p = 0,0002). К�о��е того, в небольшой г�уппе  больных (6) с 
эксп�ессией ��ути�ованного IGHV3-21-гена у 3 возникли солидные опухоли и 1 пациента — синд�о�� �ихте�а. У больных с 
эксп�ессией не��ути�ованного IGHV3-21-гена оп�еделяли худшие показатели OS и PFS по с�авнению с пациента��и с экс-        
п�ессией д�угих не��ути�ованных IGHV-генов. Выводы: п�едставленные данные согласуются с ��нение�� о са��остоятельно�� 
негативно�� п�огностическо�� значении для больных с ХЛЛ эксп�ессии IGHV3-21-гена вне зависи��ости от его ��утационного 
статуса. IGHV3-21-эксп�ессия была ассоции�ована с �азвитие�� вто�ичных солидных опухолей. Выявленный высокий у�овень 
го��ологии в heteroHDR3s-подг�уппе ��ожет свидетельствовать о воз��ожно�� антигенно�� влиянии в дополнение к антигенно��у           
влиянию в homHCDR3-подг�уппе, что было установлено �анее.    
Ключевые слова: х�онический ли��фолейкоз, гены ва�иабельных участков тяжелых цепей и����уноглобулинов, IGHV3-21,  
п�огностический факто�. 
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